Sign in Subscribe
Universities and colleges

Cost-Utility Analysis of CyberKnife SRS in Metastatic Spinal Tumors

Strategic Insights

— 1 min read

A team of researchers from the University of California has conducted a cost-utility study to evaluate the effectiveness and cost-effectiveness of CyberKnife stereotactic radiosurgery (SRS) in treating metastatic spinal malignancies compared to external beam radiation therapy. The study found that patients treated with CyberKnife SRS gained an additional net health benefit of 0.08 quality-adjusted life years and the calculated cost of CyberKnife SRS was $1933 less than external beam radiation therapy for comparable effectiveness.

Key Takeaways:

  • The study used decision analysis and a Markov model to simulate the outcomes of patients undergoing nonchemotherapeutic interventions for metastatic spinal tumors.
  • Costs of care were derived from Centers for Medicare and Medicaid Services fee schedules.
  • The time horizon for the analysis was limited to 12 months due to the terminal nature of the conditions and the limited life expectancy of the patient population.
  • Patients treated with CyberKnife SRS gained an additional net health benefit of 0.08 quality-adjusted life years.
  • The calculated cost of CyberKnife SRS was $1933 less than external beam radiation therapy for comparable effectiveness.
  • The incremental cost per benefit for this strategy ($41,500 per quality-adjusted life year) met payers' willingness-to-pay criteria.
  • The study concluded that CyberKnife SRS was a superior, cost-effective primary intervention for patients with metastatic spinal tumors compared to conventional external beam radiation therapy.

Statistics:

  • 0.08 quality-adjusted life years: the additional net health benefit gained by patients treated with CyberKnife SRS.
  • $1933: the calculated cost savings of CyberKnife SRS compared to external beam radiation therapy for comparable effectiveness.
  • $41,500: the incremental cost per benefit for this strategy.
  • 12 months: the time horizon for the analysis.

Sources:

  • F.J. Papatheofanis et al. (2009). COST-UTILITY ANALYSIS OF THE CYBERKNIFE SYSTEM FOR METASTATIC SPINAL TUMORS. Neurosurgery, 64(2 Suppl. S):A73-A83.
  • Centres for Medicare and Medicaid Services. (n.d.). Fee Schedules.

Read more